View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2013	Jan. 24, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Trading Symbol	NBIX
Entity Registrant Name	NEUROCRINE BIOSCIENCES INC
Entity Central Index Key	0000914475
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		67,793,709
Entity Public Float			$ 646,990,582

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 44,789	$ 63,754
Short-term investments, available-for-sale	100,950	109,259
Receivables under collaborative agreements	23	14,089
Other current assets	2,700	2,162
Total current assets	148,462	189,264
Property and equipment, net	1,771	1,900
Long-term investments		480
Restricted cash	4,443	4,335
Total assets	154,676	195,979
Current liabilities:
Accounts payable	101	911
Accrued liabilities	7,955	8,094
Current portion of deferred revenues		2,919
Current portion of cease-use liability	416	589
Current portion of deferred gain on sale of real estate	3,227	3,133
Total current liabilities	11,699	15,646
Deferred gain on sale of real estate	17,645	20,872
Deferred rent	1,982	1,840
Cease-use liability	2,680	3,097
Other liabilities	260	152
Total liabilities	34,266	41,607
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value; 110,000,000 shares authorized; issued and outstanding shares were 67,351,195 and 66,446,888 at December 31, 2013 and 2012, respectively	67	66
Additional paid-in capital	886,101	873,981
Accumulated other comprehensive gain (loss)	5	(2)
Accumulated deficit	(765,763)	(719,673)
Total stockholders' equity	120,410	154,372
Total liabilities and stockholders' equity	$ 154,676	$ 195,979

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	110,000,000	110,000,000
Common stock, shares issued	67,351,195	66,446,888
Common stock, shares outstanding	67,351,195	66,446,888

Consolidated Statements of Comprehensive (Loss) Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:
Sponsored research and development		$ 18,897	$ 10,462
Milestones and license fees	$ 2,919	34,243	66,951
Total revenues	2,919	53,140	77,413
Operating expenses:
Research and development	39,248	37,163	30,951
General and administrative	13,349	13,437	12,458
Cease-use expense		1,092	82
Total operating expenses	52,597	51,692	43,491
(Loss) income from operations	(49,678)	1,448	33,922
Other income:
Gain on sale/disposal of assets	37	32	242
Deferred gain on real estate	3,133	3,042	2,953
Investment income, net	402	489	418
Other income, net	16	14	36
Total other income	3,588	3,577	3,649
Net (loss) income	$ (46,090)	$ 5,025	$ 37,571
Net (loss) income per common share:
Basic	$ (0.69)	$ 0.08	$ 0.68
Diluted	$ (0.69)	$ 0.08	$ 0.67
Shares used in the calculation of net (loss) income per common share:
Basic	66,989	65,619	55,176
Diluted	66,989	66,946	56,347
Other comprehensive (loss) income:
Net (loss) income	$ (46,090)	$ 5,025	$ 37,571
Net unrealized gains (losses) on available-for-sale securities	7	85	(39)
Comprehensive (loss) income	$ (46,083)	$ 5,110	$ 37,532

Consolidated Statements of Stockholders Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance at Dec. 31, 2010	$ 19,345	$ 55	$ 781,607	$ (48)	$ (762,269)
Beginning balance (in shares) at Dec. 31, 2010		54,882
Net income (loss)	37,571	$ 0	0	0	37,571
Unrealized gains (losses) on investments	(39)	0	0	(39)	0
Share-based compensation	2,918	0	2,918	0	0
Issuance of common stock for restricted share units vested	0	$ 0	0	0	0
Issuance of common stock for restricted share units vested (in shares)		287
Issuance of common stock for option exercises	$ 286	$ 0	286	0	0
Issuance of common stock for option exercises (in shares)	94	94
Ending balance at Dec. 31, 2011	$ 60,081	$ 55	784,811	(87)	(724,698)
Ending balance (in shares) at Dec. 31, 2011		55,263
Net income (loss)	5,025	$ 0	0	0	5,025
Unrealized gains (losses) on investments	85	0	0	85	0
Share-based compensation	5,479	0	5,479	0	0
Issuance of common stock for restricted share units vested	0	$ 0	0	0	0
Issuance of common stock for restricted share units vested (in shares)		50
Issuance of common stock for option exercises	$ 731	$ 0	731	0	0
Issuance of common stock for option exercises (in shares)	209	209
Issuance of common stock, net of offering costs	$ 82,971	$ 11	82,960	0	0
Issuance of common stock, net of offering costs (in shares)		10,925
Ending balance at Dec. 31, 2012	154,372	$ 66	873,981	(2)	(719,673)
Ending balance (in shares) at Dec. 31, 2012		66,447
Net income (loss)	(46,090)	$ 0	0	0	(46,090)
Unrealized gains (losses) on investments	7	0	0	7	0
Share-based compensation	6,819	0	6,819	0	0
Issuance of common stock for option exercises	$ 5,302	$ 1	5,301	0	0
Issuance of common stock for option exercises (in shares)	904	904
Ending balance at Dec. 31, 2013	$ 120,410	$ 67	$ 886,101	$ 5	$ (765,763)
Ending balance (in shares) at Dec. 31, 2013		67,351

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOW FROM OPERATING ACTIVITIES
Net (loss) income	$ (46,090)	$ 5,025	$ 37,571
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	671	657	694
Gain on sale of assets	(3,170)	(3,074)	(3,195)
Cease-use expense		1,092	82
Deferred revenues	(2,919)	(34,242)	(37,027)
Deferred rent	142	305	434
Amortization of premiums on investments	2,843	3,135	2,341
Non-cash share-based compensation expense	6,819	5,479	2,918
Change in operating assets and liabilities:
Accounts receivable and other assets	13,528	(12,878)	2,813
Cease-use liability	(590)	(263)	(7,502)
Other liabilities	108	27	24
Accounts payable and accrued liabilities	(949)	(557)	149
Net cash used in operating activities	(29,607)	(35,294)	(698)
CASH FLOW FROM INVESTING ACTIVITIES
Purchases of investments	(145,328)	(166,313)	(139,099)
Sales/maturities of investments	151,281	132,520	134,276
Deposits and restricted cash	(108)	(29)	1,796
Proceeds from sales of property and equipment	40	32	245
Purchases of property and equipment	(545)	(971)	(750)
Net cash provided by (used in) investing activities	5,340	(34,761)	(3,532)
CASH FLOW FROM FINANCING ACTIVITIES
Issuance of common stock	5,302	83,702	286
Net cash provided by financing activities	5,302	83,702	286
Net change in cash and cash equivalents	(18,965)	13,647	(3,944)
Cash and cash equivalents at beginning of the year	63,754	50,107	54,051
Cash and cash equivalents at end of the year	44,789	63,754	50,107
SUPPLEMENTAL DISCLOSURES
Taxes paid	$ 0	$ 0	$ 0

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business Activities. Neurocrine Biosciences, Inc. (the Company or Neurocrine) was incorporated in California in 1992 and reincorporated in Delaware in 1996. The Company discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and a wholly owned vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of the Company and is inactive.

Principles of Consolidation. The consolidated financial statements include the accounts of Neurocrine as well as its wholly owned subsidiary. The Company does not have any significant interests in any variable interest entities. All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

Cash Equivalents. The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.

Short-Term Investments Available-for-Sale. Certain short-term investments are classified as available-for-sale and, in accordance with authoritative guidance, are carried at fair value, with the unrealized gains and losses reported in other comprehensive (loss) income. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

Concentration of Credit Risk. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that maintain safety and liquidity.

Collaboration Agreements. During the years ended December 31, 2013, 2012, and 2011, collaborative research and development agreements accounted for all of the Company’s revenue.

Property and Equipment. Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of three to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term.

Industry Segment and Geographic Information. The Company operates in a single industry segment – the discovery and development of therapeutics for the treatment of neurological and endocrine-related diseases and disorders. The Company had no foreign based operations during any of the years presented.

Impairment of Long-Lived Assets. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.

Fair Value of Financial Instruments. Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments.

Research and Development Expenses. Research and development (R&D) expenses consists primarily of salaries, payroll taxes, employee benefits, and share-based compensation charges, for those individuals involved in ongoing R&D efforts; as well as scientific contractor fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs, and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from the Company’s independent R&D efforts as well as efforts associated with collaborations and in-licensing arrangements. In addition, the Company funds R&D at other companies and research institutions under agreements, which are generally cancelable. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

Share-Based Compensation. The Company estimates the fair value of stock options using the Black-Scholes option pricing model on the date of grant. Restricted stock units are valued based on the closing price of the Company’s common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally three to four years; however, certain provisions in the Company’s equity compensation plans provide for shorter vesting periods under certain circumstances.

Investment Income, net. Investment income, net is comprised of interest and dividends earned on cash, cash equivalents and investments as well as gains and losses realized from activity in the Company’s investment portfolio. The following table presents certain information related to the components of investment income (in thousands):


	Years Ended December 31,
	2013		2012		2011
Interest income		400		489		435
Realized gains/(losses), net		2		—		(17	)

Total	$	402	$	489	$	418

Net (Loss) Income Per Share. The Company computes basic net (loss) income per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option agreements. Common share equivalents are excluded from the diluted net loss per share calculation because of their anti-dilutive effect.

Due to the net loss position in 2013, approximately 2.1 million of common share equivalents were excluded from the diluted common shares outstanding. At December 31, 2012 and 2011, the Company had approximately 1.3 million and 1.2 million, respectively, of additional common share equivalents outstanding that were included in the diluted income per share calculation. For the years ended December 31, 2013, 2012 and 2011, there were employee stock options and restricted stock units outstanding, calculated on a weighted average basis, to purchase 0.3 million, 2.2 million and 1.3 million shares of our common stock with an exercise price greater than the average market price of the underlying common shares.

Impact of Recently Issued Accounting Standards. In December 2011, the Financial Accounting Standards Board (FASB) issued accounting guidance requiring an entity to disclose information about offsetting arrangements and the impact of these arrangements on the Company’s financial position. This guidance is effective for interim and annual periods beginning on or after January 1, 2013. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.

In February 2013, the FASB amended the disclosure requirements regarding the reporting of amounts reclassified out of accumulated other comprehensive income. The amendment does not change the current requirement for reporting net income or other comprehensive income, but requires additional disclosures about significant amounts reclassified out of accumulated other comprehensive income including the effect of the reclassification on the related net income line items. This amendment was adopted prospectively by the Company effective January 1, 2013 and did not have a significant impact on the Company’s consolidated financial statements as the requirements are disclosure only in nature.

In July 2013, the FASB issued guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. The Company intends to adopt this guidance during the first quarter of 2014, and does not believe the adoption of this standard will have a material impact on the Company’s consolidated financial statements.

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

12 Months Ended

Dec. 31, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

NOTE 2. REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

Revenue Recognition Policy. Revenues under collaborative agreements and grants are recognized as research costs are incurred over the period specified in the related agreement or as the services are performed. These agreements are on a best-efforts basis, do not require scientific achievement as a performance obligation and provide for payment to be made when costs are incurred or the services are performed. All fees are nonrefundable to the collaborators. Prior to the revised multiple element guidance adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Estimating the duration of the development period includes continual assessment of development stages and regulatory requirements. If and when the Company enters into a new collaboration agreement or materially modifies an existing collaboration agreement, the Company will be required to apply the new multiple element guidance. Milestone payments are recognized as revenue upon achievement of pre-defined scientific events, which require substantive effort, and for which achievement of the milestone was not readily assured at the inception of the agreement.

AbbVie Inc. (AbbVie). In June 2010, the Company announced an exclusive worldwide collaboration with AbbVie, to develop and commercialize elagolix and all next-generation GnRH antagonists (collectively, GnRH Compounds) for women’s and men’s health. AbbVie made an upfront payment of $75 million and has agreed to make additional development and regulatory event based payments of up to $480 million and up to an additional $50 million in commercial event based payments. The Company has assessed event based payments under the revised authoritative guidance for research and development milestones and determined that event based payments prior to commencement of a Phase III clinical study, as defined in the agreement, meet the definition of a milestone in accordance with authoritative guidance as (1) they are events that can only be achieved in part on the Company’s past performance, (2) there is substantive uncertainty at the date the arrangement was entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Development and regulatory event based payments subsequent to the commencement of a Phase III clinical study, however, currently do not meet these criteria as their achievement is based on the performance of AbbVie. During the year ended December 31, 2011, the Company recognized $30.0 million in milestone revenue under the AbbVie collaboration, $10.0 million of which was related to advancing elagolix into Phase II clinical trials for uterine fibroids and $20.0 million of which was related to the outcome of an elagolix pre- Phase III meeting with the U.S. Food and Drug Administration (FDA) for endometriosis. As of December 31, 2013, there are no further event based payments that meet the definition of a milestone in accordance with authoritative guidance.

Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing and commercialization costs. The Company received funding for certain internal collaboration expenses which included reimbursement from AbbVie for internal and external expenses related to the GnRH Compounds through the end of 2012. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. Under the terms of the Company’s agreement with AbbVie, the collaboration effort between the parties to advance GnRH Compounds towards commercialization was governed by a joint development committee with representatives from both the Company and AbbVie. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company. The Company’s participation in the joint development committee was determined to be a substantive deliverable under the contract, and therefore, the upfront payment was deferred and recognized over the term of the joint development committee, which was completed, as scheduled, in December 2012. During 2012, the Company recorded $13.1 million in revenue related to completion of the collaborative development period which is included in sponsored research and development revenue.

There was no revenue recognized in 2013 related to this collaboration. During the years ended December 31, 2012 and 2011, revenues recognized under the collaboration agreement with AbbVie were as follows (in millions):


	Year Ended December 31,
	2012		2011
Milestones and amortization of up-front license fees	$	29.1	$	59.0
Sponsored research and development		17.8		9.1

Revenues recognized under the AbbVie collaboration agreement	$	46.9	$	68.1

Boehringer Ingelheim International GmbH (Boehringer Ingelheim). In June 2010, the Company announced a worldwide collaboration with Boehringer Ingelheim to research, develop and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Under the terms of the Company’s agreement with Boehringer Ingelheim, the Company and Boehringer Ingelheim worked jointly, during a two year collaborative research period which ended in June 2012, to identify and advance GPR119 agonist candidates into preclinical development. Following the collaborative research period, Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products, if any. The Company received a $10 million upfront payment, and received research funding to support discovery efforts. Boehringer Ingelheim agreed to make payments of up to approximately $3 million in additional preclinical milestone payments and payments of up to approximately $223 million in clinical development and commercial event based payments. The Company has assessed milestones under the revised authoritative guidance for research and development milestones and determined that the preclinical milestone payments, as defined in the agreement, meet the definition of a milestone as (1) they are events that can only be achieved in part on the Company’s performance or upon the occurrence of a specific outcome resulting from the Company’s performance, (2) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Clinical development and commercial milestone payments, however, currently do not meet these criteria as their achievement is solely based on the performance of Boehringer Ingelheim. No milestone payments were recognized during the periods presented. The Company will be entitled to a percentage of any future worldwide sales of GPR119 agonists. Under the terms of the agreement, the collaboration effort between the parties to identify and advance GPR119 agonist candidates into preclinical development was initially governed by a steering committee with representatives from both the Company and Boehringer Ingelheim; provided, however, that final decision making authority rested with Boehringer Ingelheim. The Company’s participation in the steering committee was determined to be a substantive deliverable under the contract, and therefore, the upfront payment was deferred and recognized over the two-year term of the steering committee which was completed, as scheduled, in June 2012. Boehringer Ingelheim may terminate the agreement at its discretion upon prior written notice to the Company. In such event, the Company may be entitled to specified payments and product rights would revert to the Company.


	Year Ended December 31,
	2012		2011
Amortization of up-front license fees	$	2.2	$	5.0
Sponsored research and development		1.0		1.3

Revenues recognized under the Boehringer Ingelheim collaboration agreement	$	3.2	$	6.3

Dainippon Sumitomo Pharma Co., Ltd. (DSP). In October 2007, the Company entered into an exclusive license agreement with DSP, under which the Company licensed rights to indiplon to DSP and agreed to collaborate with DSP on the development and commercialization of indiplon in Japan. Pursuant to the license agreement, among other things, the Company received an up-front license fee of $20 million. The Company is also eligible to receive additional event based payments upon specified future events related to the development and commercialization of indiplon in Japan. Should all event based payments be achieved, the Company may be entitled to payments totaling an additional $115 million. Event based payments under the DSP agreement do not meet the criteria of a milestone in accordance with the authoritative guidance as they are based on the performance of DSP. Additionally, the Company is entitled to royalties from DSP on future sales of indiplon in Japan. For each of the years ending December 31, 2013, 2012 and 2011, the Company amortized annually into revenue $2.9 million of the upfront license fee under the DSP agreement.

GlaxoSmithKline (GSK). In July 2001, the Company announced a worldwide collaboration with GSK to develop and commercialize CRF antagonists for psychiatric, neurological and gastrointestinal diseases. Under the terms of this agreement, the Company and GSK conducted a collaborative research program and collaborated in the development of Neurocrine’s current lead CRF compounds, as well as novel back-up candidates and second generation compounds identified through the collaborative research. The Company recognized $0.1 million in revenue under the GSK agreement in each of the years ended December 31, 2012 and 2011.

In September 2012, the Company and GSK entered into a Termination Agreement, pursuant to which the parties mutually agreed to terminate the collaboration agreement. Pursuant to the terms of the Termination Agreement, GSK’s license to the Company’s CRF assets terminated, reverting all rights to the Company and GSK assigned to the Company all patent rights created from the sponsored research portion of the collaboration agreement, including all related regulatory filings and approvals. GSK also assigned to the Company all other patents, regulator and technology assets that were owned or controlled by GSK and its affiliates necessary for the development and commercialization of CRF antagonist compounds.

INVESTMENTS

12 Months Ended

Dec. 31, 2013

Investments Schedule [Abstract]

INVESTMENTS

NOTE 3. INVESTMENTS

Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

Investments at December 31, 2013 and 2012 consisted of the following (in thousands):


	Years Ended December 31,
	2013		2012
Certificates of deposit	$	11,012	$	12,434
Commercial paper		4,997		19,695
Corporate debt securities		77,441		77,610
Securities of government-sponsored entities		7,500		—

Total investments	$	100,950	$	109,739

The following is a summary of investments classified as available-for-sale securities (in thousands):


	Contractual Maturity (in years)		Amortized Cost		Gross Unrealized Gains(1)		Gross Unrealized Losses(1)			Aggregate Estimated Fair Value
December 31, 2013:
Classified as current assets:
Certificates of deposit		Less than 1	$	11,018	$	1	$	(7	)	$	11,012
Commercial paper		Less than 1		4,997		—		—			4,997
Corporate debt securities		Less than 1		77,430		19		(8	)		77,441
Securities of government-sponsored entities		Less than 1		7,500		—		—			7,500

Total short-term available-for-sale securities			$	100,945	$	20	$	(15	)	$	100,950

December 31, 2012:
Classified as current assets:
Certificates of deposit		Less than 1	$	11,960	$	—	$	(6	)	$	11,954
Commercial paper		Less than 1		19,713		—		(18	)		19,695
Corporate debt securities		Less than 1		77,588		33		(11	)		77,610

Total short-term available-for-sale securities			$	109,261	$	33	$	(35	)	$	109,259

Classified as non-current assets:
Certificates of deposit		1 to 2	$	480	$	—	$	—		$	480

Total long-term available-for-sale securities			$	480	$	—	$	—		$	480

(1)	Unrealized gains and losses are included in other comprehensive income.

The following table presents certain information related to sales and maturities of available-for-sale investments (in thousands):


	Year Ended December 31,
	2013		2012		2011
Proceeds from sales/maturities of available-for-sale securities	$	151,283	$	132,520	$	134,259
Gross realized gains on sales of available-for-sale securities		2		—		—
Gross realized losses on sales of available-for-sale securities		—		—		17
Gains reclassified out of accumulated other comprehensive (loss) income into earnings		—		—		—

The following table presents information about available-for-sale investments in an unrealized loss position (in thousands):


	Less Than 12 Months					12 Months or Greater				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
December 31, 2013:
Certificates of deposit	$	9,802	$	(7	)	$	—	$	—	$	9,802	$	(7	)
Corporate debt securities		29,919		(8	)		—		—		29,919		(8	)

Total	$	39,721	$	(15	)	$	—	$	—	$	39,721	$	(15	)

December 31, 2012:
Certificates of deposit	$	10,273	$	(6	)	$	—	$	—	$	10,273	$	(6	)
Commercial paper		19,695		(18	)		—		—		19,695		(18	)
Corporate debt securities		37,524		(11	)		—		—		37,524		(11	)

Total	$	67,492	$	(35	)	$	—	$	—	$	67,492	$	(35	)

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2013

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 4. FAIR VALUE MEASUREMENTS

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:


Level 1:		Observable inputs such as quoted prices in active markets;

Level 2:		Inputs include quoted prices for similar instruments in active markets and/or quoted prices for identical or similar instruments in markets that are not active near the measurement date; and

Level 3:		Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company classifies its cash equivalents and available for sale investments within Level 1 or Level 2. The fair value of the Company’s high quality investment grade corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not reclassify any investments between levels in the fair value hierarchy during the years ended December 31, 2013 and 2012.

The Company’s assets which are measured at fair value on a recurring basis as of December 31, 2013 and 2012 were determined using the inputs described above (in millions):


				Fair Value Measurements Using
	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
December 31, 2013:
Classified as current assets:
Cash and money market funds	$	34.9		$	34.9		$	—		$	—
Certificates of deposit		11.0			11.0			—			—
Commercial paper		5.0			—			5.0			—
Securities of government-sponsored entities		7.5			—			7.5			—
Corporate debt securities		87.4			—			87.4			—

Subtotal		145.8			45.9			99.9			—
Classified as long-term assets:
Certificates of deposit		4.4			4.4			—			—

Total		150.2			50.3			99.9			—
Less cash, cash equivalents and restricted cash		(49.2	)		(39.3	)		(9.9	)		—

Total investments	$	101.0		$	11.0		$	90.0		$	—

December 31, 2012:
Classified as current assets:
Cash and money market funds	$	53.2		$	53.2		$	—		$	—
Certificates of deposit		11.9			11.9			—			—
Commercial paper		25.7			—			25.7			—
Corporate debt securities		82.2			—			82.2			—

Subtotal		173.0			65.1			107.9			—
Classified as long-term assets:
Certificates of deposit		4.8			4.8			—			—

Total		177.8			69.9			107.9			—
Less cash, cash equivalents and restricted cash		(68.1	)		(57.5	)		(10.6	)		—

Total investments	$	109.7		$	12.4		$	97.3		$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2013

Commitments And Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7. COMMITMENTS AND CONTINGENCIES

Real Estate. In December 2007, the Company closed the sale of its facility and associated real property for a purchase price of $109 million. Concurrent with the sale, the Company retired the entire $47.7 million in mortgage debt previously outstanding with respect to the facility and associated real property, and received cash of $61.0 million net of transaction costs and debt retirement.

Upon the closing of the sale of the facility and associated real property, the Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building. The ultimate result of this real estate sale was a net gain of $39.1 million which was deferred in accordance with authoritative guidance. For the years ended December 31, 2013, 2012 and 2011, the Company recognized $3.1 million, $3.0 million and $3.0 million, respectively, of the deferred gain and will recognize the remaining $20.9 million of the deferred gain over the initial Lease term which will expire at the end of 2019.

Under the terms of the Lease and the Amendments, the Company pays base annual rent (subject to an annual fixed percentage increase), plus a 3.5% annual management fee, property taxes and other normal and necessary expenses associated with the Lease such as utilities, repairs and maintenance. In lieu of a cash security deposit under the Lease, Wells Fargo Bank, N.A. issued on the Company’s behalf a letter of credit in the amount of $4.2 million, which is secured by a deposit of equal amount with the same bank. The Company also has the right to extend the Lease for two consecutive ten-year terms.

In December 2010, the Company entered into a sublease agreement (Sublease) for approximately 16,000 square feet of the Rear Building. The Sublease is expected to result in approximately $0.6 million of rental income per year over the three year term of the Sublease and is recorded as an offset to rent expense. The Sublease provides an option to extend for two one-year renewal periods. The income generated under the Sublease is lower than the Company’s financial obligation under the Lease for the Rear Building with DMH, as determined on a per square foot basis. Consequently, at December 31, 2010 the Company was required to record a cease-use liability for the net present value estimated difference between the expected income to be generated under the Sublease and future subleases and the Lease obligation over the remaining term of the Lease for the space that is occupied by the subtenant. This transaction resulted in $2.5 million of gross cease-use expense, and a reversal of $173,000 in associated deferred rent, being recorded in December 2010. In August 2012, the Company extended the terms of the Sublease and increased the leased square footage to approximately 17,000 square feet. This transaction resulted in approximately $150,000 of gross cease-use expense, and a reversal of $15,000 in associated deferred rent, being recorded in September 2012.

In September 2011, the Company entered into a second sublease agreement (Second Sublease) for approximately 3,300 square feet of space in the Rear Building. The Second Sublease is expected to result in approximately $0.1 million in rental income per year over the three year term and is recorded as an offset to rent expense. The Second Sublease provides an option to extend for a one-year renewal period which was exercised in 2013. Similar to the Sublease, the Second Sublease resulted in $0.3 million of gross cease-use expense, and a reversal of $47,000 in associated deferred rent, being recorded in September 2011.

In November 2012, the Company entered into a third sublease agreement (Third Sublease) for approximately 14,000 square feet of space in the Rear Building. The Third Sublease is expected to result in approximately $0.5 million in rental income per year over the three and a half year term and is recorded as an offset to rent expense. The Third Sublease provides the subtenant with an option to extend the term for two one-year renewal periods. Similar to the previous subleases, the Third Sublease resulted in $1.2 million of gross cease-use expense, and a reversal of $250,000 in associated deferred rent, being recorded in December 2012.

The following table sets forth changes to the accrued cease-use liability during 2013 and 2012 (in thousands):


	Years Ended December 31,
	2013			2012
Beginning balance	$	3,686		$	2,592
Impact of Sublease cease-use charges(1)		—			1,360
Change in estimate		—			(3	)
Payments		(590	)		(263	)

Ending balance	$	3,096		$	3,686

(1)	Total sublease cease-use expense was offset by a related adjustment to deferred rent of approximately $265,000 during 2012.

Rent Expense. Rent expense was $5.9 million, $5.9 million and $6.2 million for the years ended December 31, 2013, 2012 and 2011, respectively. For financial reporting purposes, the Company recognizes rent expense on a straight-line basis over the term of the lease. Accordingly, rent expense recognized in excess of rent paid is reflected as a liability in the accompanying consolidated balance sheets.

Lease Commitments. The Company leases its office and research laboratories under an operating lease with an initial term of twelve years, expiring at the end of 2019. Additionally, the Company’s facility lease agreement calls for it to maintain $50 million in cash and investments at all times, or to increase the security deposit by $5 million.

As of December 31, 2013, the total estimated future annual minimum lease payments under the Company’s non-cancelable building lease for the years ending after December 31, 2013 are as follows (in thousands):


	Payment Amount
2014	$	7,169
2015		7,385
2016		7,606
2017		7,834
2018		8,070
Thereafter		8,311

Total future minimum lease payments	$	46,375

Product Liability. The Company’s business exposes it to liability risks from its potential drug products. A successful product liability claim or series of claims brought against the Company could result in payment of significant amounts of money and divert management’s attention from running the business. The Company may not be able to maintain insurance on acceptable terms, or the insurance may not provide adequate protection in the case of a product liability claim. To the extent that product liability insurance, if available, does not cover potential claims, the Company would be required to self-insure the risks associated with such claims. The Company believes that it carries reasonably adequate insurance for product liability claims.

Licensing and Research Agreements. The Company has entered into inlicensing agreements with various universities and research organizations, which are generally cancelable at the option of the Company with terms ranging from 0-180 days written notice. Under the terms of these agreements, the Company has received licenses to research tools, know-how and technology claimed, in certain patents or patent applications. The Company is required to pay fees, milestones and/or royalties on future sales of products employing the technology or falling under claims of a patent, and some of the agreements require minimum royalty payments. Some of the agreements also require the Company to pay expenses arising from the prosecution and maintenance of the patents covering the inlicensed technology. The Company continually reassesses the value of the license agreements and cancels them when research efforts are discontinued on these programs. If all inlicensed and research candidates are successfully developed, the Company may be required to pay milestone payments of approximately $1 million over the lives of these agreements, in addition to royalties on sales of the affected products at rates ranging up to 5%. Due to the uncertainties of the development process, the timing and probability of the milestone and royalty payments cannot be accurately estimated.

Litigation. From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations.

SHARE-BASED COMPENSATION

12 Months Ended

Dec. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

SHARE-BASED COMPENSATION

NOTE 8. SHARE-BASED COMPENSATION

Share-Based Compensation Plans. In May 2011, the Company adopted the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan (the 2011 Plan) pursuant to which 7.0 million shares of Company common stock were reserved for future issuance. The 2011 Plan is the successor to the Company’s 2003 Incentive Stock Plan, 2001 Stock Option Plan, 1997 Incentive Stock Plan, 1996 Director Stock Option Plan and 1992 Incentive Stock Plan (together, the Prior Plans). Although the Company no longer grants equity awards under the Prior Plans, all outstanding stock awards granted under the Prior Plans will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the Prior Plans, as applicable.

The 2011 Plan provides for the grant of stock options that qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (the Code), nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of equity compensation, as well as performance cash awards.

Since 1992, the Company has authorized approximately 22.2 million shares of common stock for issuance pursuant to the Prior Plans, several Employment Commencement Nonstatutory Stock Option Agreements and the 2011 Plan (collectively, the Option Plans). The Option Plans provide for the grant of stock options, restricted stock awards, restricted stock unit awards, and stock bonuses to officers, directors, employees, and consultants of the Company. Currently, all new grants of stock options are made from the 2011 Plan or through Employment Commencement Nonstatutory Stock Option Agreements. As of December 31, 2013, of the 22.2 million shares originally reserved for issuance under the Option Plans, 4.2 million of these shares were originally reserved for issuance pursuant to the terms of the Prior Plans and would currently be available for issuance but for the Company’s determination not to make further grants under these plans; 8.9 million were issued upon exercise of stock options or pursuant to restricted stock or stock bonus awards; 6.2 million were subject to outstanding options and restricted stock units; and 2.9 million remained available for future grant under the 2011 Plan. Share awards made under the 2011 Plan that are subsequently cancelled due to forfeiture or expiration are returned to the share pool available for future grants.

The Company issues new shares upon the exercise of stock options, the issuance of stock bonus awards and vesting of restricted stock units, and has 9.1 million shares of common stock reserved for such issuance as of December 31, 2013.

Vesting Provisions of Share-Based Compensation. Stock options granted under the Option Plans have terms from seven to ten years from the date of grant, and generally vest over a three to four-year period. Restricted stock units granted under the Option Plans generally have vesting periods of four years. The maximum contractual term for all options granted from the 2011 Plan is ten years.

Share-Based Compensation. The compensation cost that has been included in the statement of comprehensive (loss) income for all share-based compensation arrangements is as follows (in thousands):


	Years Ended December 31,
	2013		2012		2011
General and administrative expense	$	3,516	$	2,746	$	1,760
Research and development expense		3,303		2,733		1,158

Share-based compensation expense	$	6,819	$	5,479	$	2,918

Authoritative guidance requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised be classified as cash inflows provided by financing activities and cash outflows used in operating activities. Due to the Company’s net tax loss position, no tax benefits have been recognized in the consolidated statements of cash flows.

Stock Options. The exercise price of all options granted during the years ended December 31, 2013, 2012 and 2011 was equal to the closing price of the Company’s common stock on the date of grant. The estimated fair value of each option award granted was determined on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions for option grants during the three years ended December 31, 2013:


	Years Ended December 31,
	2013			2012			2011
Risk-free interest rate		1.4	%		1.3	%		1.4	%
Expected volatility of common stock		76	%		79	%		82	%
Dividend yield		0.0	%		0.0	%		0.0	%
Expected option term		7.3 years			6.8 years			6.2 years

The Company estimates the fair value of stock options using a Black-Scholes option-pricing model on the date of grant. The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options. The expected option term is estimated based on historical experience as well as the status of the employee. For example, Directors and Officers have a longer expected option term than all other employees. Additionally, recent grants of stock options have a contractual life of ten years, versus seven years for older option grants, and the vesting period for recent option grants has been extended to four years, which together have resulted in an increase in the expected option term. The risk-free rate for periods within the contractual life of the option is based upon observed interest rates appropriate for the expected term of the Company’s employee stock options. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.

Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Pre-vesting forfeitures for awards with monthly vesting terms were estimated to be 0% in 2013 based on historical experience. Pre-vesting forfeitures for awards with annual vesting terms were also estimated at 0% in 2013 based on historical employee turnover experience. The effect of past restructurings has been excluded from the historical review of employee turnover. The effect of pre-vesting forfeitures for awards has historically been negligible on the Company’s recorded expense. The Company’s determination of fair value is affected by the Company’s stock price as well as a number of assumptions that require judgment. The weighted-average fair values of options granted during the years ended December 31, 2013, 2012 and 2011, estimated as of the grant date using the Black-Scholes option valuation model, were $6.55, $6.05 and $4.14, respectively.

A summary of the status of the Company’s stock options as of December 31, 2013, 2012 and 2011 and of changes in options outstanding under the plans during the three years ended December 31, 2013 is as follows (in thousands, except for weighted average exercise price data):


	2013					2012					2011
	Options			Weighted Average Exercise Price		Options			Weighted Average Exercise Price		Options			Weighted Average Exercise Price
Outstanding at January 1		6,166		$	7.62		5,315		$	8.82		4,047		$	11.22
Granted/amended		771			9.24		1,446			8.50		1,605			5.90
Exercised		(904	)		5.96		(209	)		3.49		(94	)		3.05
Canceled		(180	)		25.68		(386	)		29.66		(243	)		31.73

Outstanding at December 31		5,853		$	7.54		6,166		$	7.62		5,315		$	8.82

Options outstanding at December 31, 2013 have a weighted average remaining contractual term of 5.8 years.

For the year ended December 31, 2013, share-based compensation expense related to stock options was $6.0 million. As of December 31, 2013, there was approximately $8.8 million of unamortized compensation cost related to stock options, which is expected to be recognized over a weighted average vesting period of approximately 2.1 years. As of December 31, 2013, there were approximately 4.3 million options exercisable with a weighted average exercise price of $7.30 and a weighted-average remaining contractual term of 4.9 years. The total intrinsic value, which is the amount by which the exercise price was exceeded by the sale price of the Company’s common stock on the date of sale, of stock option exercises during the years ended December 31, 2013, 2012, and 2011 was $6.0 million, $943,000 and $423,000, respectively. As of December 31, 2013, the total intrinsic value of options outstanding and exercisable was $15.6 million. Cash received from stock option exercises for the years ended December 31, 2013, 2012 and 2011 was $5.3 million, $731,000 and $286,000, respectively.

On January 16, 2014 the Company granted its employees approximately 0.8 million options that vest monthly over a four year period with a strike price of $19.59.

Restricted Stock Units. Certain employees receive restricted stock units under the 2011 Plan. The fair value of restricted stock units is based on the closing sale price of the Company’s common stock on the date of issuance. The total number of restricted stock awards expected to vest is adjusted by estimated forfeiture rates, which has been based on historical experience of equity awards and historical employee turnover experience. The effect of pre-vesting forfeitures for awards has historically been negligible on the Company’s recorded expense and was estimated at 0% in 2013. The effect of past restructurings has been excluded from the historical review of employee turnover. For the year ended December 31, 2013, 2012 and 2011, share-based compensation expense related to restricted stock units was $0.8 million, $0, and $0.5 million, respectively. As of December 31, 2013, there was approximately $2.4 million of unamortized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average vesting period of approximately 3.0 years.

The total intrinsic value of restricted stock units converted into common shares during the years ended December 31, 2013, 2012 and 2011 was $0, $0.4 million, and $1.9 million, respectively. The restricted stock units, at the election of eligible employees, may be subject to deferred delivery arrangement. The total intrinsic value of restricted stock units outstanding at December 31, 2013 was $3.5 million based on the Company’s closing stock price on that date.

A summary of the status of the Company’s restricted stock units as of December 31, 2013, 2012 and 2011 and of changes in restricted stock units outstanding under the plans for the three years ended December 31, 2013 is as follows (in thousands, except for weighted average grant date fair value per unit):


	2013					2012					2011
	Number of Units			Weighted Average Grant Date Fair Value per Unit		Number of Units			Weighted Average Grant Date Fair Value per Unit		Number of Units			Weighted Average Grant Date Fair Value per Unit
Restricted stock units outstanding at January 1		—		$	—		50		$	5.88		287		$	5.08
Restricted stock units granted		379			8.65		—			—		50			5.88
Restricted stock units cancelled		(6	)		8.65		—			—		—			—
Restricted stock units converted into common shares		—			—		(50	)		5.88		(287	)		5.08

Restricted stock units outstanding at December 31		373		$	8.65		—		$	—		50		$	5.88

On January 16, 2014 the Company granted its employees approximately 0.4 million restricted stock units that vest annually over a four year period, and approximately 0.5 million restricted stock units that are subject to performance based vesting.

INCOME TAXES

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 10. INCOME TAXES

On January 1, 2007, the Company adopted the provisions of the FASB’s authoritative accounting guidance, which, among other things, related to uncertain tax positions. Under the accounting guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

There were no unrecognized tax benefits as of the date of adoption. As a result of the implementation of the guidance, the Company did not recognize an increase in the liability for unrecognized tax benefits and did not have any unrecognized tax benefits included in the balance sheet that would, if recognized, affect the effective tax rate. The adoption of the guidance did not impact the Company’s financial condition, results of operations or cash flows.

The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s consolidated balance sheets at December 31, 2013 or December 31, 2012, and has not recognized interest and/or penalties in the statement of comprehensive (loss) income for the year ended December 31, 2013.

The Company is subject to taxation in the United States and various state jurisdictions. The Company’s tax years for 1995 and forward are subject to examination by the United States and California tax authorities due to the carry forward of unutilized net operating losses and R&D credits.

At December 31, 2013, the Company had deferred tax assets of $341.7 million. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation has been established to offset the net deferred tax asset. Additionally, the future utilization of the Company’s net operating loss and research and development credit carry forwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. The Company has determined that no ownership changes have occurred through December 31, 2013.

At December 31, 2013, the Company had Federal and California income tax net operating loss carry forwards of approximately $624.9 million and $612.3 million, respectively. The Federal and California tax loss carry forwards will begin to expire in 2021 and 2015, respectively, unless previously utilized. In addition, the Company has Federal and California R&D tax credit carry forwards of $32.6 million and $22.7 million, respectively. The Federal research and development tax credit carry forwards begin expiring in 2018 and will continue to expire unless utilized. The California research and development tax credit carryforwards carry forward indefinitely. The Company also has Federal Alternative Minimum Tax credit carryforwards of approximately $241,000, which will carry forward indefinitely. At December 31, 2013, approximately $18.2 million of the net operating loss carry forwards relate to stock option exercises, which will result in an increase to additional paid-in capital and a decrease in income taxes payable at the time when the tax loss carryforwards are utilized.

Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are listed below. A valuation allowance of $341.7 million and $321.2 million at December 31, 2013 and 2012, respectively, has been recognized to offset the deferred tax assets as realization of such assets is uncertain. Amounts are shown as of December 31 as of each respective year (in thousands):


	2013			2012
Deferred tax assets:
Net operating losses	$	246,500		$	236,500
Research and development credits		27,700			25,600
Capitalized research and development		34,500			21,000
Share-based compensation expense		5,200			4,900
Deferred revenue		800			2,000
Deferred gain on sales leaseback		8,500			9,800
Intangibles		13,200			15,800
Cease-use expense		1,300			1,500
Fixed assets		300			200
Other		3,700			3,900

Total deferred tax assets		341,700			321,200
Valuation allowance		(341,700	)		(321,200	)

Net deferred tax assets	$	—		$	—

The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2013, 2012 and 2011, due to the following (in thousands):


	2013			2012			2011
Federal income taxes at 35%	$	(16,131	)	$	1,759		$	13,150
State income tax, net of Federal benefit		(2,611	)		406			2,230
Tax effect on non-deductible expenses		7			9			43
Share-based compensation expense		215			1,154			385
Expired tax attributes		151			327			159
Research credits		(3,458	)		(428	)		(3,395	)
(Re-established)/removal of net operating losses and R&D credits		—			—			(278,778	)
Change in valuation allowance		20,504			(4,061	)		248,803
Uncertain tax positions		1,283			876			17,432
Other		40			(42	)		(29	)

	$	—		$	—		$	—

The following table summarizes the activity related to our unrecognized tax benefits (in thousands):


	2013		2012			2011
Balance as of the beginning of the year	$	21,672	$	20,237		$	—
Increases related to prior year tax positions		543		1,434			19,922
Increases related to current year tax positions		916		165			395
Expiration of the statute of limitations for the assessment of taxes		—		(164	)		(80	)

Balance as of the end of the year	$	23,131	$	21,672		$	20,237

The Company has concluded that an ownership change did not occur in the current or prior years. However, the Company, under authoritative guidance, excluded those deferred tax assets that are not more likely than not to be sustained under the technical merits of the tax position. These unrecognized tax benefits totaled $0.5 million and $0.9 million for prior year tax positions and current year tax positions, respectively, as reflected in the tabular rollforward above.

As of December 31, 2013, the Company had $19.6 million of unrecognized tax benefits that, if recognized and realized, would effect the effective tax rate.

In the next twelve months, the Company does not expect a significant change in their unrecognized tax benefits.

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Cash Equivalents

Short-Term Investments Available-for-Sale

Concentration of Credit Risk

Collaboration Agreements

Collaboration Agreements. During the years ended December 31, 2013, 2012, and 2011, collaborative research and development agreements accounted for all of the Company’s revenue.

Property and Equipment

Industry Segment and Geographic Information

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

Research and Development Expenses

Share-Based Compensation

Investment Income, net


	Years Ended December 31,
	2013		2012		2011
Interest income		400		489		435
Realized gains/(losses), net		2		—		(17	)

Total	$	402	$	489	$	418

Net (Loss) Income Per Share

Impact of Recently Issued Accounting Standards

Revenue Recognition Policy

INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2013

Investments Schedule [Abstract]

Investments

Investments at December 31, 2013 and 2012 consisted of the following (in thousands):


	Years Ended December 31,
	2013		2012
Certificates of deposit	$	11,012	$	12,434
Commercial paper		4,997		19,695
Corporate debt securities		77,441		77,610
Securities of government-sponsored entities		7,500		—

Total investments	$	100,950	$	109,739

Summary of Investments Classified as Available-For-Sale Securities

The following is a summary of investments classified as available-for-sale securities (in thousands):


	Contractual Maturity (in years)		Amortized Cost		Gross Unrealized Gains(1)		Gross Unrealized Losses(1)			Aggregate Estimated Fair Value
December 31, 2013:
Classified as current assets:
Certificates of deposit		Less than 1	$	11,018	$	1	$	(7	)	$	11,012
Commercial paper		Less than 1		4,997		—		—			4,997
Corporate debt securities		Less than 1		77,430		19		(8	)		77,441
Securities of government-sponsored entities		Less than 1		7,500		—		—			7,500

Total short-term available-for-sale securities			$	100,945	$	20	$	(15	)	$	100,950

December 31, 2012:
Classified as current assets:
Certificates of deposit		Less than 1	$	11,960	$	—	$	(6	)	$	11,954
Commercial paper		Less than 1		19,713		—		(18	)		19,695
Corporate debt securities		Less than 1		77,588		33		(11	)		77,610

Total short-term available-for-sale securities			$	109,261	$	33	$	(35	)	$	109,259

Classified as non-current assets:
Certificates of deposit		1 to 2	$	480	$	—	$	—		$	480

Total long-term available-for-sale securities			$	480	$	—	$	—		$	480

(1)	Unrealized gains and losses are included in other comprehensive income.

Sales and Maturities of Available-For-Sale Investments

The following table presents certain information related to sales and maturities of available-for-sale investments (in thousands):


	Year Ended December 31,
	2013		2012		2011
Proceeds from sales/maturities of available-for-sale securities	$	151,283	$	132,520	$	134,259
Gross realized gains on sales of available-for-sale securities		2		—		—
Gross realized losses on sales of available-for-sale securities		—		—		17
Gains reclassified out of accumulated other comprehensive (loss) income into earnings		—		—		—

Available-For-Sale Investments in Unrealized Loss Position

The following table presents information about available-for-sale investments in an unrealized loss position (in thousands):


	Less Than 12 Months					12 Months or Greater				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
December 31, 2013:
Certificates of deposit	$	9,802	$	(7	)	$	—	$	—	$	9,802	$	(7	)
Corporate debt securities		29,919		(8	)		—		—		29,919		(8	)

Total	$	39,721	$	(15	)	$	—	$	—	$	39,721	$	(15	)

December 31, 2012:
Certificates of deposit	$	10,273	$	(6	)	$	—	$	—	$	10,273	$	(6	)
Commercial paper		19,695		(18	)		—		—		19,695		(18	)
Corporate debt securities		37,524		(11	)		—		—		37,524		(11	)

Total	$	67,492	$	(35	)	$	—	$	—	$	67,492	$	(35	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2013

Fair Value Disclosures [Abstract]

Assets Measured at Fair Value on Recurring Basis

The Company’s assets which are measured at fair value on a recurring basis as of December 31, 2013 and 2012 were determined using the inputs described above (in millions):


				Fair Value Measurements Using
	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
December 31, 2013:
Classified as current assets:
Cash and money market funds	$	34.9		$	34.9		$	—		$	—
Certificates of deposit		11.0			11.0			—			—
Commercial paper		5.0			—			5.0			—
Securities of government-sponsored entities		7.5			—			7.5			—
Corporate debt securities		87.4			—			87.4			—

Subtotal		145.8			45.9			99.9			—
Classified as long-term assets:
Certificates of deposit		4.4			4.4			—			—

Total		150.2			50.3			99.9			—
Less cash, cash equivalents and restricted cash		(49.2	)		(39.3	)		(9.9	)		—

Total investments	$	101.0		$	11.0		$	90.0		$	—

December 31, 2012:
Classified as current assets:
Cash and money market funds	$	53.2		$	53.2		$	—		$	—
Certificates of deposit		11.9			11.9			—			—
Commercial paper		25.7			—			25.7			—
Corporate debt securities		82.2			—			82.2			—

Subtotal		173.0			65.1			107.9			—
Classified as long-term assets:
Certificates of deposit		4.8			4.8			—			—

Total		177.8			69.9			107.9			—
Less cash, cash equivalents and restricted cash		(68.1	)		(57.5	)		(10.6	)		—

Total investments	$	109.7		$	12.4		$	97.3		$	—

SHARE-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Compensation Expenses Related to Share Based Compensation

The compensation cost that has been included in the statement of comprehensive (loss) income for all share-based compensation arrangements is as follows (in thousands):


	Years Ended December 31,
	2013		2012		2011
General and administrative expense	$	3,516	$	2,746	$	1,760
Research and development expense		3,303		2,733		1,158

Share-based compensation expense	$	6,819	$	5,479	$	2,918

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model

The estimated fair value of each option award granted was determined on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions for option grants during the three years ended December 31, 2013:


	Years Ended December 31,
	2013			2012			2011
Risk-free interest rate		1.4	%		1.3	%		1.4	%
Expected volatility of common stock		76	%		79	%		82	%
Dividend yield		0.0	%		0.0	%		0.0	%
Expected option term		7.3 years			6.8 years			6.2 years

Summary and Changes in Stock Options Outstanding


	2013					2012					2011
	Options			Weighted Average Exercise Price		Options			Weighted Average Exercise Price		Options			Weighted Average Exercise Price
Outstanding at January 1		6,166		$	7.62		5,315		$	8.82		4,047		$	11.22
Granted/amended		771			9.24		1,446			8.50		1,605			5.90
Exercised		(904	)		5.96		(209	)		3.49		(94	)		3.05
Canceled		(180	)		25.68		(386	)		29.66		(243	)		31.73

Outstanding at December 31		5,853		$	7.54		6,166		$	7.62		5,315		$	8.82

Summary and Changes in Restricted Stock Units Outstanding


	2013					2012					2011
	Number of Units			Weighted Average Grant Date Fair Value per Unit		Number of Units			Weighted Average Grant Date Fair Value per Unit		Number of Units			Weighted Average Grant Date Fair Value per Unit
Restricted stock units outstanding at January 1		—		$	—		50		$	5.88		287		$	5.08
Restricted stock units granted		379			8.65		—			—		50			5.88
Restricted stock units cancelled		(6	)		8.65		—			—		—			—
Restricted stock units converted into common shares		—			—		(50	)		5.88		(287	)		5.08

Restricted stock units outstanding at December 31		373		$	8.65		—		$	—		50		$	5.88

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Components of Deferred Tax Assets

Amounts are shown as of December 31 as of each respective year (in thousands):


	2013			2012
Deferred tax assets:
Net operating losses	$	246,500		$	236,500
Research and development credits		27,700			25,600
Capitalized research and development		34,500			21,000
Share-based compensation expense		5,200			4,900
Deferred revenue		800			2,000
Deferred gain on sales leaseback		8,500			9,800
Intangibles		13,200			15,800
Cease-use expense		1,300			1,500
Fixed assets		300			200
Other		3,700			3,900

Total deferred tax assets		341,700			321,200
Valuation allowance		(341,700	)		(321,200	)

Net deferred tax assets	$	—		$	—

Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate

The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2013, 2012 and 2011, due to the following (in thousands):


	2013			2012			2011
Federal income taxes at 35%	$	(16,131	)	$	1,759		$	13,150
State income tax, net of Federal benefit		(2,611	)		406			2,230
Tax effect on non-deductible expenses		7			9			43
Share-based compensation expense		215			1,154			385
Expired tax attributes		151			327			159
Research credits		(3,458	)		(428	)		(3,395	)
(Re-established)/removal of net operating losses and R&D credits		—			—			(278,778	)
Change in valuation allowance		20,504			(4,061	)		248,803
Uncertain tax positions		1,283			876			17,432
Other		40			(42	)		(29	)

The following table summarizes the activity related to our unrecognized tax benefits (in thousands):


	2013		2012			2011
Balance as of the beginning of the year	$	21,672	$	20,237		$	—
Increases related to prior year tax positions		543		1,434			19,922
Increases related to current year tax positions		916		165			395
Expiration of the statute of limitations for the assessment of taxes		—		(164	)		(80	)

Balance as of the end of the year	$	23,131	$	21,672		$	20,237

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - shares shares in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Organization And Summary Of Significant Accounting Policies [Line Items]
Additional dilutive potential common shares										1,300	1,200
Diluted common shares outstanding	67,346	67,199	66,799	66,600	67,720	66,342	66,309	63,409	66,989	66,946	56,347
Anti-dilutive common stock share not included in computation of diluted earnings per share									300	2,200	1,300
Entity First Incorporation
Organization And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation									1992
Place of incorporation									California
Entity Second Incorporation
Organization And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation									1996
Place of incorporation									Delaware
Minimum
Organization And Summary Of Significant Accounting Policies [Line Items]
Requisite service period of award									3 years
Maximum
Organization And Summary Of Significant Accounting Policies [Line Items]
Requisite service period of award									4 years

Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Jun. 30, 2010	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 31, 2007
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues recognized under the Boehringer Ingelheim collaboration agreement											$ 18,897	$ 10,462
Revenues		$ 730	$ 729	$ 730	$ 730	$ 21,947	$ 9,357	$ 10,569	$ 11,267	$ 2,919	53,140	77,413
Dainippon Sumitomo Pharma Co Ltd
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive													$ 115,000
Up-front license fees													$ 20,000
Amortization of up-front license fees										2,900	$ 2,900	2,900
AbbVie
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	$ 75,000
Milestone revenue												30,000
Collaborative arrangement right description											The Company received funding for certain internal collaboration expenses which included reimbursement from AbbVie for internal and external expenses related to the GnRH Compounds through the end of 2012. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.
Patent rights period											Ten years or the life of the related patent rights
Collaboration termination notice period						180 days					180 days
Revenues recognized under the AbbVie collaboration agreement										0	$ 46,900	68,100
AbbVie \| Development and regulatory event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	480,000
AbbVie \| Commercial event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	50,000
AbbVie \| Uterine Fibroids
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue												10,000
AbbVie \| Endometriosis
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue												20,000
AbbVie \| Collaboration
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues recognized under the Boehringer Ingelheim collaboration agreement											13,100
GlaxoSmithKline
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues											100	100
Boehringer Ingelheim International GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	$ 10,000
Revenues recognized under the Boehringer Ingelheim collaboration agreement										$ 0	$ 3,200	$ 6,300
Collaborative research period	2 years
Deferred upfront payment recognition period	2 years
Boehringer Ingelheim International GmbH \| Preclinical milestone payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	$ 3,000
Boehringer Ingelheim International GmbH \| Clinical development and commercial event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	$ 223,000

Summary of Investments Classified as Available-For-Sale Securities (Detail) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Schedule of Available-for-sale Securities [Line Items]

Aggregate Estimated Fair Value

$ 100,950

$ 109,739

Certificates of deposit

Schedule of Available-for-sale Securities [Line Items]

Aggregate Estimated Fair Value

11,012

12,434

Commercial paper

Schedule of Available-for-sale Securities [Line Items]

Aggregate Estimated Fair Value

4,997

19,695

Corporate debt securities

Schedule of Available-for-sale Securities [Line Items]

Aggregate Estimated Fair Value

77,441

77,610

Securities of government-sponsored entities

Schedule of Available-for-sale Securities [Line Items]

Aggregate Estimated Fair Value

7,500

Short-term investments

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

100,945

109,261

Gross Unrealized Gains

^[1]

Gross Unrealized Losses

^[1]

(15)

(35)

Aggregate Estimated Fair Value

$ 100,950

$ 109,259

Short-term investments | Certificates of deposit

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Amortized Cost

$ 11,018

$ 11,960

Gross Unrealized Gains

^[1]

Gross Unrealized Losses

^[1]

(7)

(6)

Aggregate Estimated Fair Value

$ 11,012

$ 11,954

Short-term investments | Commercial paper

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Amortized Cost

$ 4,997

$ 19,713

Gross Unrealized Losses

^[1]

(18)

Aggregate Estimated Fair Value

$ 4,997

$ 19,695

Short-term investments | Corporate debt securities

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Amortized Cost

$ 77,430

$ 77,588

Gross Unrealized Gains

^[1]

Gross Unrealized Losses

^[1]

(8)

(11)

Aggregate Estimated Fair Value

$ 77,441

77,610

Short-term investments | Securities of government-sponsored entities

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Amortized Cost

$ 7,500

Aggregate Estimated Fair Value

$ 7,500

Long-term investments

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

480

Aggregate Estimated Fair Value

480

Long-term investments | Certificates of deposit

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

480

Aggregate Estimated Fair Value

$ 480

Long-term investments | Certificates of deposit | Minimum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Long-term investments | Certificates of deposit | Maximum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

2 years

[1]	Unrealized gains and losses are included in other comprehensive income.

Available-For-Sale Investments in Unrealized Loss Position (Detail) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	$ 39,721	$ 67,492
Less Than 12 Months, Unrealized Losses	(15)	(35)
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	39,721	67,492
Total Unrealized Losses	(15)	(35)
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	9,802	10,273
Less Than 12 Months, Unrealized Losses	(7)	(6)
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	9,802	10,273
Total Unrealized Losses	(7)	(6)
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value		19,695
Less Than 12 Months, Unrealized Losses		(18)
12 Months or Greater, Estimated Fair Value		0
12 Months or Greater, Unrealized Losses		0
Total Estimated Fair Value		19,695
Total Unrealized Losses		(18)
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	29,919	37,524
Less Than 12 Months, Unrealized Losses	(8)	(11)
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	29,919	37,524
Total Unrealized Losses	$ (8)	$ (11)

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	1 Months Ended								12 Months Ended
	Dec. 31, 2012 USD ($)	Nov. 30, 2012 USD ($) ft²	Sep. 30, 2012 USD ($)	Aug. 31, 2012 ft²	Aug. 30, 2012 USD ($)	Sep. 30, 2011 USD ($) ft²	Dec. 31, 2010 USD ($) ft²	Dec. 31, 2007 USD ($) Building	Dec. 31, 2013 USD ($) RenewalOptions	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2008 USD ($)
Commitment And Contingencies [Line Items]
Sale of facility and associated real property								$ 109,000
Mortgage debt retired								47,700
Cash received net of transaction costs and debt retirement								$ 61,000
Leaseback transaction lease period								12 years
Number of building leased \| Building								2
Net deferred gain on real estate sale									$ 20,900			$ 39,100
Deferred gain recognized on real estate sale									$ 3,100	$ 3,000	$ 3,000
Lease expiration year									2019
Percentage of management fee included in the base annual rent									3.50%
Letter of credit									$ 4,200
Lease extension period									10 years
Number of times to renew the lease contract \| RenewalOptions									2
Cease-use expense										1,092	82
Rent expense									$ 5,900	$ 5,900	$ 6,200
Lease period									12 years
Lease expiration year									2019
Cash and investment required to be maintained									$ 50,000
Security deposit to be increased									5,000
Milestone payables									$ 1,000
Minimum
Commitment And Contingencies [Line Items]
Lease cancellation, notice period									0 days
Maximum
Commitment And Contingencies [Line Items]
Lease cancellation, notice period									180 days
Royalty, rate									5.00%
Sublease
Commitment And Contingencies [Line Items]
Subleased area \| ft²				17,000			16,000
Rental income from sublease agreement							$ 600
Sublease agreement period							3 years
Lease renewal additional periods							1 year
Cease-use expense					$ 150		$ 2,500
Deferred rent reversed			$ 15				$ 173
Second Sublease
Commitment And Contingencies [Line Items]
Subleased area \| ft²						3,300
Rental income from sublease agreement						$ 100
Sublease agreement period						3 years
Lease renewal additional periods						1 year
Cease-use expense						$ 300
Deferred rent reversed						$ 47
Third Sublease
Commitment And Contingencies [Line Items]
Subleased area \| ft²		14,000
Rental income from sublease agreement		$ 500
Sublease agreement period		3 years 6 months
Lease renewal additional periods		1 year
Cease-use expense		$ 1,200
Deferred rent reversed	$ 250

Estimated Future Annual Minimum Lease Payments (Detail) $ in Thousands	Dec. 31, 2013 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2014	$ 7,169
2015	7,385
2016	7,606
2017	7,834
2018	8,070
Thereafter	8,311
Total future minimum lease payments	$ 46,375

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		12 Months Ended
	Jan. 16, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	May 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of common stock reserved for future issuance		22,200
Number of common stock available for future grant		2,900
Restricted stock, vesting period		4 years
Share-based compensation, contractual term		10 years
Assumption estimated forfeiture rate		0.00%
Weighted-average fair values of options granted		$ 6.55	$ 6.05	$ 4.14
Weighted average remaining contractual term for options outstanding		5 years 9 months 18 days
Share-based compensation expense		$ 6,819	$ 5,479	$ 2,918
Number of stock options exercisable		4,300
Stock options exercisable, weighted average exercise price		$ 7.30
Stock options exercisable, weighted-average remaining contractual term		4 years 10 months 24 days
Stock options exercised in period intrinsic value		$ 6,000	943	423
Stock options intrinsic value of options outstanding and exercisable		15,600
Cash received from stock option exercises		$ 5,300	$ 731	$ 286
Stock options granted		771	1,446	1,605
Share-based compensation, exercise price		$ 9.24	$ 8.50	$ 5.90
Minimum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation, term		3 years
Maximum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation, term		4 years
Share-based compensation, contractual term		10 years
Stock Options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense		$ 6,000
Unrecognized compensation cost		$ 8,800
Stock vesting period		2 years 1 month 6 days
Stock Options \| Subsequent Event
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Restricted stock, vesting period	4 years
Stock options granted	800
Share-based compensation, exercise price	$ 19.59
Stock Options \| Minimum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation, term		7 years
Restricted stock, vesting period		3 years
Stock Options \| Maximum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation, term		10 years
Restricted stock, vesting period		4 years
Restricted Stock Units (RSUs)
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Restricted stock, vesting period	4 years
Assumption estimated forfeiture rate		0.00%
Share-based compensation expense		$ 800	$ 0	$ 500
Unrecognized compensation cost		$ 2,400
Stock vesting period		3 years
Total intrinsic value vested in period		$ 0	$ 400	$ 1,900
Intrinsic value outstanding		$ 3,500
Restricted stock units granted		379		50
Restricted Stock Units (RSUs) \| Subsequent Event
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Restricted stock units granted	400
Restricted Stock Units (RSUs) \| Minimum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Restricted stock, vesting period		4 years
Restricted Stock Units (RSUs) \| Performance Based Vesting [Member] \| Subsequent Event
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Restricted stock units granted	500
Share Based Compensation Arrangement Award
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of common stock reserved for future issuance		9,100
Due to Changes in the Plan \| Scenario, Previously Reported
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation, contractual term		7 years
2011 Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of common stock reserved for future issuance					7,000
Prior Plans
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of common stock reserved for future issuance		4,200
Stock Options, Restricted Stock Units or Stock Bonus Plans
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of common stock reserved for future issuance		8,900
Stock Options and Restricted Stock Unit Plans
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of common stock reserved for future issuance		6,200

Summary and Changes in Stock Options Outstanding (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Shares
Outstanding, Beginning Balance	6,166	5,315	4,047
Granted/amended	771	1,446	1,605
Exercised	(904)	(209)	(94)
Canceled	(180)	(386)	(243)
Outstanding, Ending Balance	5,853	6,166	5,315
Weighted average exercise price
Outstanding, Beginning Balance	$ 7.62	$ 8.82	$ 11.22
Granted/amended	9.24	8.50	5.90
Exercised	5.96	3.49	3.05
Canceled	25.68	29.66	31.73
Outstanding, Ending Balance	$ 7.54	$ 7.62	$ 8.82

Summary and Changes in Restricted Stock Units Outstanding (Detail) - Restricted Stock Units (RSUs) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restricted stock units
Restricted stock units outstanding, Beginning Balance		50	287
Restricted stock units granted	379		50
Restricted stock units cancelled	(6)
Restricted stock units converted into common shares		(50)	(287)
Restricted stock units outstanding Ending Balance	373		50
Weighted average grant date fair value
Restricted stock units outstanding Beginning Balance		$ 5.88	$ 5.08
Restricted stock units granted	$ 8.65		5.88
Restricted stock units cancelled	8.65
Restricted stock units converted into common shares		$ 5.88	5.08
Restricted stock units outstanding Ending Balance	$ 8.65		$ 5.88

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 01, 2007
Income Taxes [Line Items]
Percentage of uncertain tax positions likelihood of being sustained	50.00%
Unrecognized tax benefits	$ 23,131	$ 21,672	$ 20,237	$ 0
Accrual interest or penalties	0	0
Deferred tax assets	341,700	321,200
Research and development tax credit carry forwards	27,700	25,600
Net operating loss carry forwards related to stock option exercises	18,200
Deferred tax assets, valuation allowance	341,700	321,200
Increases related to prior year tax positions	543	1,434	19,922
Increases related to current year tax positions	916	$ 165	$ 395
Unrecognized tax benefits that would affect effective tax rate	19,600
Federal
Income Taxes [Line Items]
Operating loss carry forward, net	$ 624,900
Operating loss carry forward beginning expiration year	2021
Research and development tax credit carry forwards	$ 32,600
Alternative Minimum Tax credit carry forwards	$ 241
Federal \| R&D
Income Taxes [Line Items]
Tax credit carry forwards beginning expiration year	2018
California
Income Taxes [Line Items]
Operating loss carry forward, net	$ 612,300
Operating loss carry forward beginning expiration year	2015
Research and development tax credit carry forwards	$ 22,700

Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Net operating losses	$ 246,500	$ 236,500
Research and development credits	27,700	25,600
Capitalized research and development	34,500	21,000
Share-based compensation expense	5,200	4,900
Deferred revenue	800	2,000
Deferred gain on sales leaseback	8,500	9,800
Intangibles	13,200	15,800
Cease-use expense	1,300	1,500
Fixed assets	300	200
Other	3,700	3,900
Total deferred tax assets	341,700	321,200
Valuation allowance	(341,700)	(321,200)
Net deferred tax assets	$ 0	$ 0

Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]
Federal income taxes at 35%	$ (16,131)	$ 1,759	$ 13,150
State income tax, net of Federal benefit	(2,611)	406	2,230
Tax effect on non-deductible expenses	7	9	43
Share-based compensation expense	215	1,154	385
Expired tax attributes	151	327	159
Research credits	(3,458)	(428)	(3,395)
(Re-established)/removal of net operating losses and R&D credits			(278,778)
Change in valuation allowance	20,504	(4,061)	248,803
Uncertain tax positions	1,283	876	17,432
Other	40	(42)	(29)
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0

Summary of Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 730	$ 729	$ 730	$ 730	$ 21,947	$ 9,357	$ 10,569	$ 11,267	$ 2,919	$ 53,140	$ 77,413
Operating expenses	12,260	12,735	13,897	13,705	13,365	13,319	11,949	13,059	52,597	51,692	43,491
Net income (loss)	$ (10,642)	$ (11,131)	$ (12,242)	$ (12,075)	$ 9,490	$ (3,078)	$ (501)	$ (886)	$ (46,090)	$ 5,025	$ 37,571
Net income (loss) per share:
Basic	$ (0.16)	$ (0.17)	$ (0.18)	$ (0.18)	$ 0.14	$ (0.05)	$ (0.01)	$ (0.01)	$ (0.69)	$ 0.08	$ 0.68
Diluted	$ (0.16)	$ (0.17)	$ (0.18)	$ (0.18)	$ 0.14	$ (0.05)	$ (0.01)	$ (0.01)	$ (0.69)	$ 0.08	$ 0.67
Shares used in the calculation of net income (loss) per share:
Basic	67,346	67,199	66,799	66,600	66,406	66,342	66,309	63,409	66,989	65,619	55,176
Diluted	67,346	67,199	66,799	66,600	67,720	66,342	66,309	63,409	66,989	66,946	56,347

STOCKHOLDERS' EQUITY	12 Months Ended
STOCKHOLDERS' EQUITY	Dec. 31, 2013
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9. STOCKHOLDERS’ EQUITY *Equity Financing* In January 2012, the Company completed a public offering of common stock in which the Company sold 10.9 million shares of its common stock at an offering price of $8.10 per share. The shares were sold pursuant to a shelf registration statement previously on file with the SEC. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $83.0 million. *Shelf Registration Statement* In December 2012, the SEC declared effective a shelf registration statement filed by the Company in November 2012. The shelf registration statement allows the Company to issue shares of its common stock from time to time for an aggregate initial offering price of up to $150 million. The specific terms of future offerings, if any, under the shelf registration statement would be established at the time of such offerings.

RETIREMENT PLAN	12 Months Ended
RETIREMENT PLAN	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]
RETIREMENT PLAN	NOTE 11. RETIREMENT PLAN The Company has a 401(k) defined contribution savings plan (401(k) Plan). The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $0.3 million, $0.2 million and $0.2 million for the years ended December 31, 2013, 2012 and 2011, respectively.

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2013
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12. SUBSEQUENT EVENTS The Company evaluated all subsequent events that have occurred after the date of the accompanying financial statements and determined that there were no events or transactions occurring during this subsequent event reporting period which require recognition or disclosure in the Company’s financial statements, other than as disclosed below.

Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	$ 101.0	$ 109.7
Fair Value, Measurements, Recurring \| Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	150.2	177.8
Fair Value, Measurements, Recurring \| Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	(49.2)	(68.1)
Short-term investments \| Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	145.8	173.0
Short-term investments \| Fair Value, Measurements, Recurring \| Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	34.9	53.2
Short-term investments \| Fair Value, Measurements, Recurring \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	11.0	11.9
Short-term investments \| Fair Value, Measurements, Recurring \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	5.0	25.7
Short-term investments \| Fair Value, Measurements, Recurring \| Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	7.5
Short-term investments \| Fair Value, Measurements, Recurring \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	87.4	82.2
Long-term investments \| Fair Value, Measurements, Recurring \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	4.4	4.8
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	11.0	12.4
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	50.3	69.9
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	39.3	57.5
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	45.9	65.1
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	34.9	53.2
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	11.0	11.9
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Long-term investments \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	4.4	4.8
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	90.0	97.3
Significant Other Observable Inputs (Level 2) \| Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	99.9	107.9
Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	9.9	10.6
Significant Other Observable Inputs (Level 2) \| Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	99.9	107.9
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	5.0	25.7
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	7.5
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	87.4	82.2
Significant Other Observable Inputs (Level 2) \| Long-term investments \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Long-term investments \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	$ 0.0	$ 0.0

Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Payables And Accruals [Abstract]
Accrued employee related costs	$ 3,403	$ 3,811
Accrued development costs	1,387	1,231
Other accrued liabilities	3,165	3,052
Accrued Liabilities, Current	$ 7,955	$ 8,094

Investments (Detail) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Schedule of Investments [Line Items]
Investments	$ 100,950	$ 109,739
Certificates of deposit
Schedule of Investments [Line Items]
Investments	11,012	12,434
Commercial paper
Schedule of Investments [Line Items]
Investments	4,997	19,695
Corporate debt securities
Schedule of Investments [Line Items]
Investments	77,441	$ 77,610
Securities of government-sponsored entities
Schedule of Investments [Line Items]
Investments	$ 7,500

Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Property and equipment	$ 30,103	$ 36,223
Less accumulated depreciation	(28,332)	(34,323)
Property and equipment, net	1,771	1,900
Tenant improvements
Property, Plant and Equipment [Line Items]
Property and equipment	1,195	1,195
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment	819	819
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment	$ 28,089	$ 34,209

Changes to Accrued Cease-Use Liability (Parenthetical) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($)
Sublease
Lease Commitments And Contingencies [Line Items]
Deferred rent reversed	$ 265

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Stock [Line Items]
Common stock issued	10.9
Common stock, offering price	$ 8.10
Proceeds from common stock issuance	$ 83,000	$ 5,302	$ 83,702	$ 286
Shelf Registration \| Maximum
Class of Stock [Line Items]
Aggregate initial offering price of common stock			$ 150,000